Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bamlanivimab - Abcellera/Eli Lilly and Company

Drug Profile

Bamlanivimab - Abcellera/Eli Lilly and Company

Alternative Names: ABCL-555; LY 3819253; LY CoV 555

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Abcellera; Eli Lilly and Company
  • Developer Abcellera; Eli Lilly and Company; National Institute of Allergy and Infectious Diseases
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Registered COVID 2019 infections

Most Recent Events

  • 10 Oct 2023 9399857 - Financing info added
  • 04 Aug 2023 Phase-III clinical trials in COVID-2019 infections (Combination therapy) in Nigeria (IV) (NCT04501978) (EudraCT2020-003278-37)
  • 14 Jul 2023 National Institute of Allergy and Infectious Diseases (NIAID) completes a phase-III trial in COVID-2019 infections (Combination therapy) in Singapore, Denmark, Spain, Switzerland, Nigeria, Greece, United Kingdom, USA, Uganad, Poland (IV) (NCT04501978) (EudraCT2020-003278-37)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top